Thr34
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr34  -  Survivin (human)

Site Information
FLEGCACtPERMAEA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447705
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 27 ) , immunoassay ( 3 , 17 ) , immunoprecipitation ( 17 ) , mass spectrometry ( 5 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 18 , 19 ) , microscopy-colocalization with upstream kinase ( 25 ) , mutation of modification site ( 6 , 22 , 23 , 24 , 26 , 27 ) , phospho-antibody ( 2 , 3 , 4 , 17 , 20 , 21 , 22 , 23 , 25 , 27 ) , western blotting ( 2 , 3 , 4 , 6 , 17 , 23 , 25 )
Disease tissue studied:
breast cancer ( 23 ) , cervical cancer ( 16 ) , cervical adenocarcinoma ( 16 ) , lung cancer ( 7 , 8 ) , non-small cell lung cancer ( 8 ) , non-small cell lung adenocarcinoma ( 8 ) , non-small cell large cell lung carcinoma ( 8 ) , small-cell lung cancer ( 7 ) , OSCC ( 17 )
Relevant cell line - cell type - tissue:
'blood, plasma' ( 2 ) , 'stem, breast cancer' ( 3 ) , 293 (epithelial) ( 6 , 10 , 11 , 12 , 13 , 14 ) , DMS79 (pulmonary) ( 7 ) , eye cell ( 4 ) , HeLa (cervical) ( 5 , 9 , 19 , 20 , 23 , 24 , 25 , 27 ) , HeLa S3 (cervical) ( 16 , 18 ) , HeLa_Meta (cervical) ( 15 ) , HeLa_Pro (cervical) ( 15 ) , HeLa_Telo (cervical) ( 15 ) , LNCaP (prostate cell) ( 22 ) , lung ( 7 , 8 ) , MCF-7 (breast cell) ( 23 ) , mononuclear-blood ( 2 ) , NCI-H128 (pulmonary) ( 7 ) , NCI-H1299 (pulmonary) ( 8 ) , NCI-H1417 (pulmonary) ( 7 ) , NCI-H1734 (pulmonary) ( 8 ) , NCI-H1944 (pulmonary) ( 8 ) , NCI-H209 (pulmonary) ( 7 ) , NCI-H358 (pulmonary) ( 8 ) , NCI-H460 (pulmonary) ( 8 ) , NCI-H524 (pulmonary) ( 7 ) , squamous ( 17 ) , T lymphocyte-blood ( 21 ) , YUSAC2 (melanocyte) ( 26 , 27 )

Upstream Regulation
Putative in vivo kinases:
CDK1 (human) ( 17 , 23 , 25 , 27 )
Kinases, in vitro:
AurB (human) ( 6 ) , CDK1 (human) ( 23 , 27 )
Treatments:
adriamycin ( 23 ) , alvocidib ( 23 ) , andrographolide ( 3 ) , NU6140 ( 20 ) , purvalanol ( 20 ) , taxol ( 20 , 25 )

Downstream Regulation
Effects of modification on Survivin:
activity, induced ( 3 , 4 , 20 , 21 , 22 ) , intracellular localization ( 4 , 25 ) , molecular association, regulation ( 27 ) , protein stabilization ( 23 )
Effects of modification on biological processes:
apoptosis, inhibited ( 23 , 24 , 26 , 27 ) , carcinogenesis, induced ( 17 ) , cell growth, altered ( 4 , 21 ) , cytoskeletal reorganization ( 25 ) , signaling pathway regulation ( 4 ) , transcription, induced ( 2 , 6 ) , transcription, inhibited ( 6 )
Induce interaction with:
CASP9 (human) ( 27 )

Disease / Diagnostics Relevance
Relevant diseases:
OSCC ( 17 ) , occular surface disease ( 4 )

References 

1

Benaiges E, et al. (2021) Survivin drives tumor-associated macrophage reprogramming: a novel mechanism with potential impact for obesity. Cell Oncol (Dordr)
33710603   Curated Info

2

Pahlavan Y, Samadi N, Ansarin K, Khabbazi A (2020) Phosphorylation Modulates Survivin Function in Behcet's Disease. Adv Pharm Bull 10, 278-283
32373497   Curated Info

3

Wanandi SI, et al. (2020) In silico and in vitro studies on the anti-cancer activity of andrographolide targeting survivin in human breast cancer stem cells. PLoS One 15, e0240020
33211707   Curated Info

4

Xu YX, et al. (2014) Differential expression and function of survivin during the progress of pterygium. Invest Ophthalmol Vis Sci 55, 8480-7
25468890   Curated Info

5

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

6

Lu J, et al. (2014) Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin. J Virol 88, 4204-17
24478433   Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

10

Guo A (2010) CST Curation Set: 9968; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

11

Guo A (2010) CST Curation Set: 9970; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

12

Guo A (2010) CST Curation Set: 9975; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

13

Guo A (2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

14

Guo A (2010) CST Curation Set: 9974; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

15

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

16

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

17

Zhou S, et al. (2008) The phosphorylation of survivin Thr34 by p34cdc2 in carcinogenesis of oral submucous fibrosis. Oncol Rep 20, 1085-91
18949405   Curated Info

18

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

19

Nousiainen M, et al. (2006) Phosphoproteome analysis of the human mitotic spindle. Proc Natl Acad Sci U S A 103, 5391-6
16565220   Curated Info

20

Pennati M, et al. (2005) Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther 4, 1328-37
16170024   Curated Info

21

Song J, et al. (2005) Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 22, 621-31
15894279   Curated Info

22

Zhang M, Latham DE, Delaney MA, Chakravarti A (2005) Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24, 2474-82
15735703   Curated Info

23

Wall NR, et al. (2003) Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63, 230-5
12517802   Curated Info

24

Temme A, et al. (2003) Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell 14, 78-92
12529428   Curated Info

25

Fortugno P, et al. (2002) Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115, 575-85
11861764   Curated Info

26

Grossman D, Kim PJ, Schechner JS, Altieri DC (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 98, 635-40
11149963   Curated Info

27

O'Connor DS, et al. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 97, 13103-7
11069302   Curated Info